

# Irbesartan

**Catalog No: tcsc2140** 

 Available Sizes

 Size: 10mg

 Size: 50mg

 Size: 100mg

 Size: 200mg

 Size: 500mg

 Size: 1g

 Specifications

 CAS No:

138402-11-6

Formula:

C<sub>25</sub>H<sub>28</sub>N<sub>6</sub>O

Pathway:

## **Target:**

Angiotensin Receptor

### Purity / Grade:

>98%

## Solubility:

DMSO : ≥ 59 mg/mL (137.68 mM)

#### **Alternative Names:**

SR-47436;BMS-186295

Copyright 2021 Taiclone Biotech Corp.



#### **Observed Molecular Weight:**

428.53


# **Product Description**

Irbesartan is a highly potent and specific angiotensin II type 1 (AT1) receptor antagonist with IC50 of 1.3 nM.

Target: Angiotensin Receptor

Irbesartan treatment markedly induces the expression of the adipogenic marker gene adipose protein 2 (aP2) in 3T3-L1 cells in a concentration-dependent manner with EC50 of 3.5  $\mu$ M and 3.3-fold induction at the concentration of 10  $\mu$ M. Irbesartan (10  $\mu$ M) markedly induces transcriptional activity of the peroxisome proliferator-activated receptor- $\gamma$  (PPAR $\gamma$ ) by 3.4-fold independent of its AT1 receptor blocking action. Pretreatment with Irbesartan (~10  $\mu$ M) decreases angiotensin II-induced apoptosis in rat vascular smooth muscle cells by blocking angiotensin II internalization in a concentrationdependent manner.

Oral administration of Irbesartan (1 mg/kg) reduces angiotensin II (AII)-induced hypertension, equipotent with losartan in conscious normotensive rats, markedly more active than losartan (10 mg/kg) in normotensive cynomolgus monkeys. Administration of Irbesartan (7 mg/kg/day) significantly prevents skeletal muscle apoptosis and muscle atrophy in rats with monocrotaline-induced congestive heart failure (CHF), which is involved with the decrease of TNFα level and attributed to AT1 receptor blocking.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!

Copyright 2021 Taiclone Biotech Corp.